Onconetix Financials
Onconetix (ONCO) reported $815K in revenue for fiscal year 2025, down 67.7% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Higher gross margins are being overwhelmed by operating overhead, leaving financing—not operations—to support the balance sheet.
Gross margin expanded from41.8% in FY2024 to77.6% in FY2025, yet operating margin remained deeply negative at-21.9% . The combination indicates that improved economics after direct costs are still too small to absorb the operating structure, rather than a problem confined to production costs.
FY2025 operating cash flow was
The balance sheet is dominated by goodwill of
Financial Health Signals
Onconetix does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Onconetix scores -9.68, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($2.6M) relative to total liabilities ($9.2M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Onconetix passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, all 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
Onconetix reported a net loss of $14.0M while operations used $9.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Onconetix reported an operating loss of $17.9M against $751K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Onconetix generated $815K in revenue in fiscal year 2025. This represents a decrease of 67.7% from the prior year.
Onconetix's EBITDA was -$17.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 68.0% from the prior year.
Onconetix reported -$14.0M in net income in fiscal year 2025. This represents an increase of 76.1% from the prior year.
Cash & Balance Sheet
Onconetix held $5.2M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Onconetix's gross margin was 77.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 35.8 percentage points from the prior year.
Onconetix's ROE was -89.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 598.0 percentage points from the prior year.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
None of these metrics is reported for fiscal year 2025.
ONCO Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|---|
| Revenue | $646K | $815K-67.7% | $2.5M+4217.3% | $58K | N/A | N/A |
| Cost of Revenue | $127K | $182K-87.6% | $1.5M+23.9% | $1.2M | N/A | N/A |
| Gross Profit | $519K | $633K-40.0% | $1.1M+193.6% | -$1.1M | N/A | N/A |
| R&D Expenses | N/A | N/A | $154K-92.1% | $1.9M-52.8% | $4.1M+211.7% | $1.3M |
| SG&A Expenses | $8.1M | $7.0M-37.3% | $11.2M-24.0% | $14.8M+57.9% | $9.4M+346.9% | $2.1M |
| Operating Income | -$16.3M | -$17.9M+68.4% | -$56.5M-56.8% | -$36.0M-167.3% | -$13.5M-294.5% | -$3.4M |
| Interest Expense | $357K | $751K-14.0% | $873K+30.0% | $672K | N/A | N/A |
| Income Tax | N/A | $525+100.1% | -$1.0M-8199.7% | -$13K | N/A | N/A |
| Net Income | -$10.2M | -$14.0M+76.1% | -$58.7M-56.9% | -$37.4M-178.8% | -$13.4M-292.7% | -$3.4M |
| EPS (Diluted) | — | -$16.56 | -$1823.39 | -$87.45 | -$1.10 | -$1.26 |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
ONCO Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|
| Total Assets | $24.9M-11.5% | $28.2M-67.8% | $87.5M+232.6% | $26.3M+752.9% | $3.1M |
| Current Assets | $6.1M+538.4% | $950K-83.7% | $5.8M-77.8% | $26.3M+754.4% | $3.1M |
| Cash & Equivalents | $5.2M+707.5% | $647K-85.8% | $4.6M-82.3% | $25.8M+1235.4% | $1.9M |
| Inventory | $150K+134.0% | $64K-82.4% | $364K | N/A | N/A |
| Accounts Receivable | $297K+1054.4% | $26K-82.8% | $150K | N/A | N/A |
| Goodwill | $18.5M-31.4% | $27.0M-51.4% | $55.7M | N/A | N/A |
| Total Liabilities | $9.2M-50.7% | $18.6M-80.1% | $93.1M+2274.0% | $3.9M+139.4% | $1.6M |
| Current Liabilities | $9.1M-50.0% | $18.3M+6.4% | $17.2M+338.3% | $3.9M+139.4% | $1.6M |
| Total Equity | $15.8M+84.5% | $8.5M+252.5% | -$5.6M-125.0% | $22.4M+1447.7% | $1.4M |
| Retained Earnings | -$131.2M-13.4% | -$115.7M-103.7% | -$56.8M-193.1% | -$19.4M-225.3% | -$6.0M |
Not reported in any period shown, so not listed: Long-Term Debt.
ONCO Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -$10.3M | -$9.7M+7.8% | -$10.5M+22.7% | -$13.6M-56.5% | -$8.7M-324.4% | -$2.0M |
| Capital Expenditures | N/A | N/A | $28K+762.8% | $3K-64.7% | $9K+385.4% | $2K |
| Free Cash Flow | N/A | N/A | -$10.5M+22.5% | -$13.6M-56.4% | -$8.7M-324.4% | -$2.0M |
| Investing Cash Flow | N/A | N/A | -$28K+99.7% | -$8.6M-26378.0% | -$33K-1597.8% | -$2K |
| Financing Cash Flow | $15.6M | $14.5M+114.3% | $6.7M+551.5% | $1.0M-96.8% | $32.5M+9834.8% | -$334K |
| Share Buybacks | N/A | N/A | N/A | N/A | $567K | N/A |
Not reported in any period shown, so not listed: Dividends Paid.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
ONCO Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|
| Gross Margin | 77.6%+35.8pp | 41.8% | -1927.9% | N/A | N/A |
| Operating Margin | -2190.0% | -2238.0% | -61634.5% | N/A | N/A |
| Net Margin | -1721.0% | -2325.2% | -63986.5% | N/A | N/A |
| Return on Equity | -89.0%+598.0pp | -687.0% | N/A | -59.9%+176.3pp | -236.2% |
| Return on Assets | -56.3%+152.0pp | -208.3%-165.5pp | -42.8%+8.3pp | -51.0%+59.8pp | -110.8% |
| Current Ratio | 0.66+0.6x | 0.05-0.3x | 0.34-6.4x | 6.69+4.8x | 1.88 |
| Debt-to-Equity | 0.58-1.6x | 2.17 | N/A | 0.18-1.0x | 1.13 |
| FCF Margin | N/A | -417.0% | -23235.0% | N/A | N/A |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Note: The current ratio is below 1.0 (0.66), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Where Onconetix Ranks
Frequently Asked Questions
What is Onconetix's annual revenue?
Onconetix (ONCO) reported $815K in total revenue for fiscal year 2025. This represents a -67.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Onconetix's revenue growing?
Onconetix (ONCO) revenue declined by 67.7% year-over-year, from $2.5M to $815K in fiscal year 2025.
Is Onconetix profitable?
No, Onconetix (ONCO) reported a net income of -$14.0M in fiscal year 2025.
What is Onconetix's EBITDA?
Onconetix (ONCO) had EBITDA of -$17.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Onconetix's gross margin?
Onconetix (ONCO) had a gross margin of 77.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Onconetix's return on equity (ROE)?
Onconetix (ONCO) has a return on equity of -89.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Onconetix's operating cash flow?
Onconetix (ONCO) recorded an outflow of $9.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Onconetix's total assets?
Onconetix (ONCO) had $24.9M in total assets as of fiscal year 2025, including both current and long-term assets.
What is Onconetix's current ratio?
Onconetix (ONCO) had a current ratio of 0.66 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Onconetix's debt-to-equity ratio?
Onconetix (ONCO) had a debt-to-equity ratio of 0.58 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Onconetix's return on assets (ROA)?
Onconetix (ONCO) had a return on assets of -56.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Onconetix's cash runway?
Based on fiscal year 2025 data, Onconetix (ONCO) had $5.2M in cash against an annual operating cash burn of $9.7M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Onconetix's Altman Z-Score?
Onconetix (ONCO) has an Altman Z-Score of -9.68, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Onconetix's Piotroski F-Score?
Onconetix (ONCO) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Onconetix's earnings high quality?
Onconetix (ONCO) reported a net loss of $14.0M while operations used $9.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Onconetix cover its interest payments?
Onconetix (ONCO) reported an operating loss of $17.9M against $751K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.